Ovulation inhibitors effectively treat menstrual issues and improve fertility but can have side effects.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
March 2026 in “Endocrine Metabolic & Immune Disorders - Drug Targets” Combined finasteride and spironolactone therapy significantly improves quality of life in women with PCOS.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
January 2025 in “International Journal of Medicine in Developing Countries” Ocrelizumab may cause delayed hair loss in some patients.
3 citations
,
July 2019 in “Case Reports in Obstetrics and Gynecology” A young woman's rare ovarian tumor was successfully removed, improving her hormonal symptoms.
6 citations
,
January 2023 in “Medical Mycology Journal” Fosravuconazole effectively treated a woman's scalp infection without side effects.
May 2024 in “Reactions weekly”
October 2023 in “Journal of the Endocrine Society” A woman's increased facial hair and hair loss were caused by a rare ovarian tumor, cured by surgery.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
12 citations
,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
October 2025 in “Journal of the Endocrine Society” Leydig cell tumors in the ovary can cause high testosterone and male traits in postmenopausal women but are treatable with surgery.
2 citations
,
August 2011 in “Revista Medica De Chile” A postmenopausal woman's high testosterone levels and symptoms improved after removing a tumor from her ovary.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
February 2010 in “Journal of The American Academy of Dermatology” Posaconazole is a promising new treatment for toenail fungus.
August 2021 in “Pediomaternal Nursing Journal” Endocrine therapy helps with reproductive and metabolic issues in women with PCOS.
186 citations
,
December 2011 in “Molecules” Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.
December 2022 in “Journal of Medical Case Reports” A 20-year-old woman was found to have a rare ovarian tumor causing symptoms like acne and a low-pitched voice, which disappeared after the tumor was removed.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
9 citations
,
September 2010 in “Dermatologic therapy” Combining cetirizine and topical steroids can effectively manage severe lichen planus pilaris.
March 2010 in “Ejc Supplements” ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
4 citations
,
December 2012 in “Arquivos Brasileiros De Endocrinologia E Metabologia” A postmenopausal woman's masculine symptoms improved after surgery for a hormone-producing ovarian tumor.
January 2023 in “Seven Editora eBooks” A rare ovarian tumor was diagnosed in a woman from North Brazil, and surgery is the preferred treatment.
1 citations
,
October 2020 in “Current Drug Discovery Technologies” The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
34 citations
,
May 1987 in “European Journal of Pediatrics” Buserelin safely and effectively suppresses early puberty, potentially improving final height.